Onconova Therapeutics, Inc. strengthened its team with the appointment of Adar Makovski Silverstein, Ph.D., as Director, Corporate Development.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4254 USD | -1.05% |
|
+19.83% | -42.95% |
07-02 | Traws Pharma Files for Potential Sale of 128.9 Million Shares | MT |
06-21 | Traws Pharma, Inc. Announces Resignation of Steven M. Fruchtman as President and Chief Scientific Officer, Oncology | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.95% | 10.88M | |
+25.36% | 46.56B | |
+45.38% | 41.67B | |
+0.92% | 41.16B | |
+30.65% | 32.4B | |
+22.13% | 28.18B | |
-6.35% | 28.1B | |
+48.73% | 14.52B | |
+48.33% | 13.74B | |
+3.49% | 12.17B |
- Stock Market
- Equities
- TRAW Stock
- News Traws Pharma, Inc.
- Onconova Therapeutics, Inc. Appoints Adar Makovski Silverstein as Director, Corporate Development